Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry Eye Syndrome
(WorldNews Health)

Company to Initiate Clinical Trials for Treatment of FSGS, MCD, and Dry Eye in 2018 with Data Readouts in Second Half of 2018 R&D Day Featuring KOLs in Nephrology and Ophthalmology Will be Webcast Today at 8:30a.m. ET in New York VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia) today announced plans to expand its voclosoprin renal franchise to include focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD). Additionally, Aurinia announced plans to evaluate its proprietary nanomicellar voclosporin ophthalmic solution (VOS) for the treatment of keratoconjunctivitis sicca or dry eye syndrome (DES). The advancement...